PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.44%
EBIT growth 10-15% – Solid. Seth Klarman would see if this level of profit expansion is sustainable across cycles.
10.44%
Operating income growth 10-15% – Solid. Seth Klarman would look at whether overhead costs remain controlled for long-term stability.
10.28%
Net income growth 10-15% – Solid. Seth Klarman would verify if cost control or pricing is driving consistent profit expansions.
12.12%
EPS growth 10-15% – Solid. Seth Klarman would see if share dilution or buybacks significantly affected the results.
10.49%
Diluted EPS growth 10-15% – Solid. Seth Klarman would check if share-based compensation is offsetting part of net income gains.
2.21%
Share count up to +3% – Slight dilution. Howard Marks would be cautious but might accept it if used for profitable growth investments.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.06%
Negative OCF growth is a critical warning sign. Benjamin Graham would check if receivables are ballooning or if core sales are declining.
-28.93%
Negative FCF growth reveals potential liquidity pressures or large capex overshadowing cash generation. Benjamin Graham would demand deeper scrutiny.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4997.65%
A negative 10Y OCF/share CAGR signals erosion in long-term cash generation. Benjamin Graham would label this as a major red flag.
52.56%
5Y OCF/share CAGR above 15% – Very robust mid-term cash expansion. Warren Buffett would check if reinvestment fosters sustainable growth.
56.42%
3Y OCF/share CAGR above 15% – Rapid short-term expansion. Warren Buffett would see if this stems from genuine operational improvements vs. working-capital swings.
-10058.37%
A negative 10Y net income/share CAGR reflects a decade of weakening profits. Benjamin Graham would be extremely cautious unless a turnaround is evident.
92.69%
5Y net income/share CAGR above 15% – Strong mid-term profit growth. Benjamin Graham would check if leverage artificially boosts earnings.
51.37%
3Y net income/share CAGR above 15% – Rapid short-term profit growth. Benjamin Graham would verify if it’s driven by core revenue or temporary cost reductions.
741.48%
10Y equity/share CAGR above 12% – Excellent long-term book value compounding. Warren Buffett would see if consistent profits plus moderate payouts drive this growth.
108.54%
5Y equity/share CAGR above 12% – Strong mid-term book value expansion. Warren Buffett would see if steady profits and moderate payout ratios sustain this pace.
-89.94%
Negative 3Y equity/share CAGR means a near-term drop in book value. Benjamin Graham would be cautious unless restructured operations promise a future rebound.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.83%
Negative asset growth may reflect divestitures or depreciation outpacing new investments. Benjamin Graham wonders if shedding non-core assets improves focus or signals trouble.
-40.69%
Falling book value/share indicates net losses, large dividends, or intangible impairments. Benjamin Graham warns unless there’s a strategic reason.
499.58%
Debt growing over 10% yoy – Potentially high risk. Philip Fisher demands a clear rationale and profitable expansions to offset the debt load.
-14.73%
A big drop in R&D might boost near-term earnings but risk starving the pipeline. Benjamin Graham sees if the firm is refocusing or if future growth suffers.
3.54%
SG&A growth 0-5% – Generally manageable. Seth Klarman sees if overhead remains controlled and margins intact.